Seeking Alpha

anomaly1

anomaly1
Send Message
View as an RSS Feed
View anomaly1's Comments BY TICKER:
Latest  |  Highest rated
  • Advaxis immunotherapy candidate 100% successful in anal cancer trial [View news story]
    Many of articles I've read on Advaxis have been written by employees of Advaxis.

    My colleagues in cancer immunotherapy find that many of the stated results of trials are worded improperly.
    Mar 24, 2015. 10:45 AM | Likes Like |Link to Comment
  • CorMedix: Up Too Far Too Fast [View article]
    I statement: Neutrolin is NOT approved.

    Not prudent to assume 100% of the valuation when Neutrolin approval is more than 2 years away.

    Plenty of time to buy the stock. Why get in now vs. later? Shares are being sold next from upcoming exercised warrants.
    Mar 20, 2015. 12:45 AM | Likes Like |Link to Comment
  • CorMedix: Up Too Far Too Fast [View article]
    Their track record for shorts, checked their page stats, are very good.

    The article has facts. I don't care for the horse comments.
    Mar 20, 2015. 12:42 AM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    The longs that are pumping want to make money.

    The shares being sold via warrant exercise in the upcoming weeks want to be sold for as high a price as possible, so its obvious they want to keep stock afloat by convincing holders not to sell beforehand.

    Street Sweeper states they have a short position. They are pro shorts so i would assume they know what they are talking about. Check out the performance of their previous shorts. Looks like they do well at shorting.
    Mar 19, 2015. 10:58 PM | 1 Like Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    more

    "Noting, “We will not receive any proceeds from the sale of shares registered under this prospectus,” CorMedix held the earnings call and filed a registration statement clearing shareholders to sell $19 million worth of stock.

    So, 75 stockholders can soon sell 2.45 million dilutive shares on the public market."
    Mar 19, 2015. 10:22 PM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    Watch out below....

    http://bit.ly/1ynRNXw

    "Dr. Lindsay Rosenwald, who directly and indirectly loaned ~$604,000 to CorMedix in 2009 apparently is running with the herd, too. Altogether he’s selling more than 138,000 shares.

    TheStreetSweeper first warned shareholders in July 2013 about one of biotech’s best known horse traders, Dr. Rosenwald. We told about the curly-haired Dr. Rosenwald’s interesting alliances and his bizarre whipworm egg therapeutic company, Coronado Biosciences (CNDO then ~$8, now ~$3).

    Dr. Rosenwald co-founded and financed Interneuron, maker of an anti-obesity drug. The drug was related to the “fen” in the “fen-phen” drug cocktail eventually beset by safety concerns that led to more than 3,000 lawsuits and withdrawal from the U.S. market in 1997.

    Other biotech companies he founded or heavily supported have also dumped investors head-first.

    These include:

    Avax Technologies: deregistered in March 2009, now worth under a penny.

    Biocryst: once traded at $34, now $10.

    Genta: poster child for toxic financial deals, U.S. Food and Drug Administration rejections and horrible clinical trials. FDA ultimately ruled against Genta’s cancer drugs and the company lost a crucial $480 million deal with Aventis. Genta filed for chapter 7 bankruptcy.

    Neose Technologies: filed a certificate of dissolution in March 2009. Under management’s final plan, liquidating distribution approved at $0.0121.

    Ventrus Biosciences: founded and supported by Rosenwald, traded over $21 in 2011, now trading for ~$1."
    Mar 19, 2015. 10:20 PM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    "So who can current shareholders thank for watering down their shares?

    Well, check out the entire list here, beginning on page 24. It includes:

    Biggest seller, 12-percent loan maker Galenica, casting off over 165,000 shares. Stake reduced to 1.4 percent from 2.1.
    Former company director Gary Gelbfish and his entities buck off ~96,000 shares, pushing ownership from 6.6 percent down to 6.5.
    Current director and 4.1 percent owner Steven Lefkowitz left over 992,000 shares remaining, after offering over 19,000 shares.
    Current director Matthew Duffy holds percentage steady but offers nearly 5,000 shares for sale."
    Mar 19, 2015. 10:20 PM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    "Elliott Management Corporation is an employee owned hedge fund sponsor. The firm primarily provides its services to pooled investment vehicles. It invests in the public equity, fixed income, and alternative investment markets across the globe. The firm obtains external research to complement its in-house research. Elliott Management Corporation was founded in 1977 and is based in New York City with an additional office in London, United Kingdom."

    http://bloom.bg/1x6WYh2
    Mar 19, 2015. 10:17 PM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    "CorMedix: Finishing Out Of The Money"

    Article out

    http://bit.ly/1ynRNXw

    *One CorMedix selling shareholder has jockeyed a string of decimated companies – one promotes whipworm-egg cocktails.
    Mar 19, 2015. 09:50 PM | Likes Like |Link to Comment
  • CorMedix: Up Too Far Too Fast [View article]
    "CorMedix: Finishing Out Of The Money"

    Article out

    http://bit.ly/1ynRNXw
    Mar 19, 2015. 09:48 PM | Likes Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    Elliott is an investment bank. They are paid by fees and warrant awards and board of director seats. Evercore has yet to find a partner. "...whether we go it on our own or we go it with a partner that Evercore finds, we're ready." - Tony Pfaffle ,Chief Scientific Officer. Let's stop with the buyout nonsense. Even Mr Pfaffle has clearly used the term PARTNER, not buyer. READ the following from the CC "These options might include product development collaboration, a merger or sale of assets. We are in the preparation phase and they will launch the process in the coming weeks. We are working closely with the Evercore professionals as they identify and evaluate various strategic alternatives. I want to reiterate what we have disclosed publicly, which is that, we do not know if we will succeed in this effort..." -Randy Milby, CEO. Again , no mention of a buyer. Referring Evercore's prior business dealings does not imply there is a buyer for Cormedix. Especially, if you read the contents of the CC transcript. Let's stop kicking a dead horse.
    Mar 17, 2015. 11:22 PM | 1 Like Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    My assumption is $15M in US sales in year 5 for Neutrolin, if approved. At least one more capital raise and two years away from an FDA decision.

    Let's price the company at 20X fifth yr annual revenues = $300M. SINCE NEUTROLIN IS UNAPPPROVED, discount that figure by 60%-80% for phase III = $60M-$90M market cap. Let's double that figure for 10 years of exclusivity plus intl. sales = $120M-$180M.

    Current market cap $370M. Another dilution of $20M coming to pay for trial.

    Easy to see, CRMD stock can easily go under $4 pps
    Mar 17, 2015. 11:19 PM | 1 Like Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    Conference Call 3/13 :

    "A variety of very high level people who have contributed to this effort to move the process forward and whether we go it on our own or we go it with a partner that Evercore finds, we’re ready." - Tony Pfaffle - Chief Scientific Officer

    Evercore obviously has not found a buyer for CRMD. At best a partner, but in my opinion, not until after FDA approval.
    Mar 17, 2015. 11:19 PM | 1 Like Like |Link to Comment
  • Borrow Costs Elevated On CorMedix [View article]
    you might want to read this before you speak "CorMedix Board and management has retained Evercore to evaluate and identify strategic alternatives aimed to accelerate the product's global development and commercialization"

    "Evercore as financial advisor to explore strategic alternatives"

    http://bit.ly/1EJAULY

    Financial advisor capacity , i.e. strategic alternatives, can imply buyout or partnership. SO, sell the company is your wording, not the company's wording.

    http://cnb.cx/1EJAXaD#.

    "CorMedix announced that Elliott Management has extended to the company a financing commitment to serve as a back stop in the event these warrants are not exercised; CorMedix also agreed it will amend certain warrants held by Elliott and issue 200,000 additional warrants at an exercise price of$7.00. Additionally, CorMedix granted Elliott the right to appoint two incremental board members."

    http://bit.ly/1EJAULY

    Elliott simply provided funding in exchange for warrants. Of course Cormedix pays a fee the two board members from Elliott.
    Mar 17, 2015. 11:18 PM | 1 Like Like |Link to Comment
  • Trevena Inc: Profitable To You And Disruptive To Everyone Else [View article]
    I will definitely wait for pullback.
    Mar 17, 2015. 08:33 PM | Likes Like |Link to Comment
COMMENTS STATS
912 Comments
546 Likes